Quest Diagnostics Incorporated· DGX
🇺🇸 US · LargeSP500NYSE
- Price
- $233.72
- Day
- +0.76%
- Mkt Cap
- $25.80B
- 52W Range
- $171.18 – $240.13
- Volume
- 660.6K
- Beta
- 0.57
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #ai #artificialintelligence #health #healthcare #technology #medical #patients #doctors #diagnostics #innovation #business #leadership #future #medicine #jimdavis #questdiagnostics
Read full article
DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.
Read full article
Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.
Read full article
DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.
Read full article
Largest nationally representative study finds 12% of patients positive for bacterial vaginosis are infected with at least one STI, such as chlamydia or gonorrhea SECAUCUS, N.J., July 30, 2026 /PRNewswire/ -- Women who test positive for bacterial vaginosis (BV) were over three times more likely to also test positive for one or more non-viral sexually transmitted infections (STIs) than women who test negative for BV, according to a new Health Trends® study from Quest Diagnostics (NYSE: DGX) and Hologic, Inc. In the largest national study of its kind, scientists at Quest and Hologic analyzed deidentified aggregated laboratory data from over 1.5 million women across the United States who received molecular testing from Quest between 2022 and 2024.
Read full article
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read full article
Partnerships with other healthcare leaders are accelerating Quest's growth. AI is making the health insights provider more profitable.
Read full article
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read full article
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read full article
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read full article
Quest Diagnostics earns a reiterated buy rating after Q2 earnings beat, upgraded FY guidance, and continued market momentum. DGX benefits from strong macro demand for specialized diagnostic testing, peer-leading ROE, and resilient top-line growth (+10.2% YoY). Upward earnings revisions, robust dividend growth, and investment-grade credit ratings support the bull case, though cost pressures and payor risk warrant monitoring.
Read full article
Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call Transcript
Read full article